Transcend Capital Advisors, LLC Celldex Therapeutics, Inc. Transaction History
Transcend Capital Advisors, LLC
- $1.42 Billion
- Q3 2025
A detailed history of Transcend Capital Advisors, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Transcend Capital Advisors, LLC holds 9,237 shares of CLDX stock, worth $236,005. This represents 0.02% of its overall portfolio holdings.
Number of Shares
9,237Holding current value
$236,005% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
205Shares Held
66.8MCall Options Held
222KPut Options Held
234K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$156 Million13.34% of portfolio
-
Wellington Management Group LLP Boston, MA5.8MShares$148 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$120 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.95MShares$101 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.89MShares$99.5 Million0.2% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.2B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...